Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Does LAG-3 and PD-1 inhibition have a role in treating brain metastases in melanoma?

Meredith McKean • 15 Sep 2024
ESMO 2024
Melanoma Skin Cancer Antibodies Cemiplimab Checkpoint Inhibitors Fianlimab Ipilimumab Nivolumab

Meredith McKean, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the potential role of fianlimab and cemiplimab, a LAG-3 and PD-1 inhibitor respectively, in the management of brain metastases in patients with melanoma. Existing strategies such as ipilimumab and nivolumab can penetrate the blood brain barrier, and the former combination may show signs of similar intracranial efficacy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Meredith McKean

The current state and role of LAG-3 inhibition in melanoma
0:45
The current state and role of LAG-3 inhibition in melanoma
Meredith McKean • 15 Sep 2024
Assessing LAG-3 & PD-1 inhibition with fianlimab & cemiplimab in advanced melanoma
1:50
Assessing LAG-3 & PD-1 inhibition with fianlimab & cemiplimab in advanced melanoma
Meredith McKean • 15 Sep 2024
Evaluating JZP898, an IFN-α and pembrolizumab in advanced solid tumors
0:52
Evaluating JZP898, an IFN-α and pembrolizumab in advanced solid tumors
Meredith McKean • 2 Jun 2024
Melanoma trials at ASCO 2024: KEYMAKER-U02A, IMC-F106 and SC-682
2:55
Melanoma trials at ASCO 2024: KEYMAKER-U02A, IMC-F106 and SC-682
Meredith McKean • 2 Jun 2024

Related Videos

Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
2:41
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
Alexandra Haugh • 30 May 2026
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
1:05
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
James Smithy • 31 May 2026
Optimal timing of ctDNA dynamics to prognosticate ICI efficacy in melanoma
1:26
Optimal timing of ctDNA dynamics to prognosticate ICI efficacy in melanoma
Vincent Ma • 31 May 2026
Phase Ib/II trial of PHP therapy with nivo/rela in metastatic melanoma and liver metastasis
1:42
Phase Ib/II trial of PHP therapy with nivo/rela in metastatic melanoma and liver metastasis
Vincent Ma • 31 May 2026
The content of VJOncology is intended for healthcare professionals